Response to letter entitled Re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

Eur J Cancer. 2023 Oct:192:113264. doi: 10.1016/j.ejca.2023.113264. Epub 2023 Aug 22.

Authors

Mara Persano¹, Margherita Rimini², Andrea Casadei Gardini²

Affiliations

¹ Medical Oncology, University and University Hospital of Cagliari, Italy. Electronic address: marapersano@alice.it.
² Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.

PMID: 37620209
DOI: 10.1016/j.ejca.2023.113264

No abstract available

Publication types

Letter
Comment

MeSH terms

Bevacizumab / adverse effects
Carcinoma, Hepatocellular* / drug therapy
Humans
Liver Neoplasms* / drug therapy

Substances

atezolizumab
Bevacizumab
lenvatinib